CONTEXT

Infectious diseases continue to plague and decimate populations world-wide. Among the means at our disposal to counter this threat, vaccination has proven to be exceptionally powerful. Nonetheless, severe threats continue to challenge human health, notably also from emergent viruses that have adapted and emerged as new diseases. Recent such examples are the severe threat posed by Chikungunya and Zika insect-born viruses. Ideally, a vaccine will be safe, non-replicative, efficient, and tunable with the possibility to be produced easily at industrial scale.

TECHNICAL DESCRIPTION

The present invention relates to new adenoviral coat protein based delivery vehicles. They are based on a modified penton base protomers that assemble into VLPs. Exposed areas of the penton base proteins can be modified to allow the VLP to specifically bind to any target and/or to comprise any desired peptide epitope.

DEVELOPMENT STAGE

Available vaccine particle: displaying Chikungunya epitope
In vivo (mice) PoC

BENEFITS

Rapid production
Strong immune response
Safe
Optimized antigen presentation

INDUSTRIAL APPLICATIONS

The objective is to generate a pipeline in different domains: infectious diseases, veterinary applications, therapeutic vaccines in oncology. The developments could be conducted in the frame of a start-up.

For further information, please contact us (Ref 09073-01)